<DOC>
	<DOCNO>NCT02370355</DOCNO>
	<brief_summary>This research trial study molecular characterization circulate tumor cell ( CTCs ) circulate tumor ( ct ) deoxyribonucleic acid ( DNA ) blood plasma sample patient prostate cancer spread place body and/or respond previous treatment hormone . Studying sample blood plasma collect patient prostate cancer , , and/or treatment laboratory may help doctor learn change occur DNA identify development drug resistance .</brief_summary>
	<brief_title>Molecular Characterization CTCs ctDNA Blood Plasma Samples From Patients With Metastatic and/or Hormone-Resistant Prostate Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Perform molecular analysis plasma sample 25 patient metastatic prostate cancer collect treatment disease abiraterone acetate ( Zytiga ) enzalutamide ( Xtandi ) . II . Perform molecular characterization circulate tumor cell ( CTCs ) plasma collect 75 patient progress advanced metastatic prostate cancer . OUTLINE : Patients assign 1 2 group base time specimen collection . GROUP I : Previously collect plasma sample analyze ctDNA via polymerase chain reaction ( PCR ) next generation sequencing ( NSG ) . GROUP II : Patients undergo collection blood sample follow systemic therapy analysis CTC enumeration , ribonucleic acid ( RNA ) expression , ctDNA via PCR NSG .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>GROUP I : Samples Group I select exist sample set obtain concluded study ( USC IRB # 's 1000006 1100450 ) GROUP I : Excess plasma collect stored trial patient treat abiraterone enzalutamide use molecular analysis current protocol GROUP II : The second group sample ( Group 2 ) involve prospective collection peripheral blood patient advance , treatmentresistant metastatic prostate cancer GROUP II : Histologic documentation prostate cancer GROUP II : Metastatic cancer diagnose image clinical criterion GROUP II : Treatmentresistance determine least one follow factor : increase prostatespecific antigen ( PSA ) value baseline measurement ; increase size number metastatic deposit determine image ; and/or progression cancer relate symptom</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>